abecma market size forecast and market insight

“ABECMA Market Size, Forecast, and Market Insight - 2032” report provides comprehensive insights about ABECMA for Multiple Myeloma in the seven major markets. A detailed picture of the ABECMA for Multiple Myeloma in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this report along with a detailed description of the ABECMA for Multiple Myeloma. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the ABECMA market forecast analysis for Multiple Myeloma in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in Multiple Myeloma.

Drug Summary

ABECMA (ide-cel) is a B-cell maturation antigen (BCMA)-directed genetically modified autologous chimeric antigen receptor (CAR) T-cell immunotherapy co-developed and co-promoted by Bristol Myers Squibb and Bluebird bio for the treatment of adult patients with multiple myeloma who have received at least three prior therapies. The ide-cel CAR is comprised of a murine extracellular single-chain variable fragment (scFv) specific for recognizing BCMA, attached to a human CD8 α hinge and transmembrane domain fused to the T-cell cytoplasmic signaling domains of CD137 4-1BB and CD3-ζ chain, in tandem. Ide-cel recognizes and binds to BCMA on the surface of multiple myeloma cells, leading to CAR T-cell proliferation, cytokine secretion, and subsequent cytolytic killing of BCMA-expressing cells.

The manufacturer of ABECMA, Bristol Myers Squibb, halted its UK drug approval plans in 2020 due to a combination of factors, including the impact of the pandemic on its clinical trial delivery.

Dosage and administration

ABECMA is provided as a single dose for infusion containing a suspension of chimeric antigen receptor (CAR)-positive T cells in one or more infusion bags. The recommended dose range is 300–460 × 106 CARpositive T cells

Mechanism of action

ABECMA is a chimeric antigen receptor (CAR)-positive T-cell therapy targeting B-cell maturation antigen (BCMA) expressed on the surface of normal and malignant plasma cells. The CAR construct includes an anti-BCMA scFv-targeting domain for antigen specificity, a transmembrane domain, a CD3-zeta T-cell activation domain, and a 4-1BB costimulatory domain. Antigen-specific activation of ABECMA results in CAR-positive T-cell proliferation, cytokine secretion, and subsequent cytolytic killing of BCMA-expressing cells

Scope of the Report 

The report provides insights into:

• A comprehensive product overview including the ABECMA description, mechanism of action, dosage and administration, research and development activities in Multiple Myeloma.
• Elaborated details on ABECMA regulatory milestones and other development activities have been provided in this report.
• The report also highlights the ABECMA research and development activities in Multiple Myeloma across the United States, Europe, and Japan.
• The report also covers the patents information with expiry timeline around ABECMA.
• The report contains forecasted sales of ABECMA for Multiple Myeloma till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Multiple Myeloma.
• The report also features the SWOT analysis with analyst views for ABECMA in Multiple Myeloma.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

ABECMA Analytical Perspective by DelveInsight

In-depth ABECMA Market Assessment

This report provides a detailed market assessment of ABECMA for Multiple Myeloma in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2025 to 2032.

ABECMA Clinical Assessment

The report provides the clinical trials information of ABECMA for Multiple Myeloma covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights  

• In the coming years, the market scenario for Multiple Myeloma is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.   
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence ABECMA dominance.
• Other emerging products for Multiple Myeloma are expected to give tough market competition to ABECMA and launch of late-stage emerging therapies in the near future will significantly impact the market. 
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of ABECMA in Multiple Myeloma.
• Our in-depth analysis of the forecasted sales data of ABECMA from 2025 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the ABECMA in Multiple Myeloma. 

Key Questions

• What is the product type, route of administration and mechanism of action of ABECMA?
• What is the clinical trial status of the study related to ABECMA in Multiple Myeloma and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the ABECMA development?
• What are the key designations that have been granted to ABECMA for Multiple Myeloma?
• What is the forecasted market scenario of ABECMA for Multiple Myeloma?
• What are the forecasted sales of ABECMA in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?  
• What are the other emerging products available and how are these giving competition to ABECMA for Multiple Myeloma?
• Which are the late-stage emerging therapies under development for the treatment of Multiple Myeloma?